Medidata Medidata

Biopharmaceutical company works with Acorn AI to conduct real world cost of illness studies before product launch

About Customer

A clinical-stage biopharmaceutical company focused on improving the lives of cancer patients.

The Challenge

An up-and-coming biopharmaceutical company focuses on developing novel therapeutics to improve the lives of cancer patients. The company will soon go to market with a second-line treatment for a rare type of solid tumor. In anticipation of the product launch, the company wanted to complete a cost of illness study to inform doctors and insurance companies about the economic burden of cancer treatment and the real world benefits of this new drug. This was challenging given the lack of clear treatment guidelines for the disease in its later stages.While the company previously obtained medical pharmacy claims data, it wasn’t sure whether the data would be enough for a full study. As a small startup, it also didn’t have the internal resources to conduct the study on its own.

We wanted to work with expert analysts, but we weren’t entirely sure what data we were looking for, we knew it was important to work with a company that was data agnostic and willing to look everywhere for the data we needed. Through Acorn AI, we found an expert partner who used its understanding of data to help us find the results that we needed before taking our treatment to market."        - Vice President of Market Access and HEOR

The Solution

The company invited Acorn AI, a Medidata company, to an initial consulting engagement for its expertise in working with real world data. Acorn AI quickly explored the medical claims data and conducted a feasibility study to confirm the data could support the research objectives. The company then commissioned Acorn AI to conduct a full cost of illness study based on this medical pharmacy claims data.

The Results

Vice President of Market Access and HEOR, Clinical-Stage Biopharmaceutical Company

Acorn AI is an expert partner who used its understanding of real world data to help us find the results we needed before taking our treatment to market.